Otisipharm Pro

Performance indicators

2024: Decrease in revenue by 26% to 25.33 billion rubles

At the end of 2024, the Russian pharmaceutical company Otisipharm, which produces drugs such as Arbidol, Amiksin, Pentalgin and Next, received revenue of 25.33 billion rubles. For comparison, a year earlier, the figure was 34.33 billion rubles. Thus, the fall was at 26.2%, as stated in the accounting documentation, which TAdviser got acquainted with in mid-April 2025.

Gross profit on an annualized basis decreased by 31.8% - from 25.41 billion rubles to 17.33 billion rubles. Profit from sales decreased by 38.9%, amounting to 10.41 billion rubles against 17.04 billion rubles in 2023. At the same time, profit before tax rose by 2.9% - from 10.87 billion rubles to 11.18 billion rubles. Otisipharm received 4.37 billion rubles of net profit, which is 41.1% less than in 2023, when the pharmaceutical company earned 7.41 billion rubles.

𝓲

Фото: Freepik

The cost of sales in 2024 amounted to 8 billion rubles, which is 10.4% less than in the previous year (8.93 billion rubles). Commercial expenses year-on-year decreased by 19.5% - from 7.28 billion rubles to 5.86 billion rubles. Management expenses decreased from 1.08 billion rubles to 1.06 billion rubles, that is, by 2.1%. Accounts receivable as of December 31, 2024 are indicated in the amount of 14.89 billion rubles: this is 38.4% less than the previous year (24.16 billion rubles). Accounts payable decreased by 44.7% - from 4.46 billion rubles to 2.46 billion rubles.

Revenues from sales of products, goods, works and services decreased by 39.6% year-on-year, amounting to 33.36 billion rubles against 55.26 billion rubles in 2023. Payments to suppliers (contractors) for raw materials, materials, works and services fell by 19.5% - from 14.96 billion rubles to 12.04 billion rubles.^[1]

History

2023: Opening a pharmaceutical complex near Kaliningrad for 4.8 billion rubles

On March 30, 2023, the official opening ceremony of the Otisipharm Pro drug production plant near Kaliningrad took place. This event was attended by President RFVladimir Putin.

A new enterprise in the Khrabrovo industrial park produces antiviral drugs; antiseptic and anti-inflammatory; nonsteroidal drugs; combined analgesics; antifungal agents; anxiolytic agents. The total volume of investments in fixed assets by the end of March 2023 exceeded 4.8 billion rubles.

The total volume of investments in fixed assets by the end of March 2023 exceeded 4.8 billion rubles

As the general director of Otisipharm JSC Olga Mednikova said at the opening, the Kaliningrad division will produce up to 320 million packages of drugs per year, or more than 2 billion tablets. However, the plant will not start working at full capacity immediately - this year it is planned to produce about 50 million packages, including 16 million packages of drugs included in the list of vital. What kind of drugs are we talking about here, Mednikova did not specify.

According to Mednikova, there are no acute problems with the delivery of components for the production of drugs to the Kaliningrad region.

We experience difficulties, but they are solved. Currently, the entire route is being built from St. Petersburg and so far meets all our needs and opportunities. In the future, Anton Andreevich [Alikhanov, Governor of the Kaliningrad Region] and I discussed that other opportunities would be considered. We don't see any logistical difficulties, "she said.

Anton Alikhanov, in turn, added that all the components necessary for production are imported into the region with containers. "We have no problems with container transportation, no queues for containerized cargo."^[2]

Notes